124289-21-0

Basic information

• Product Name: 3-BROMO-5-METHYLBENZONITRILE
• Synonyms: 3-BROMO-5-METHYLBENZONITRILE;3-Methyl-5-bromobenzonitrile;3-BroMo-5-Methylbenzonitrile, 95+%;Benzonitrile,3-bromo-5-methyl-;Bromo-5-methyl-benzonitrile
• CAS NO: 124289-21-0
• Molecular Formula: C₈H₆BrN
• Molecular Weight: 196.04
• Mol File: 124289-21-0.mol

Chemical Properties

• Melting Point: 57-58.5℃
• Boiling Point: 256.1±20.0℃ (760 Torr)
• Flash Point: 108.7±21.8℃
• Appearance: /
• Density: 1.51±0.1 g/cm3 (20 ºC 760 Torr)
• Vapor Pressure: 0.016mmHg at 25°C
• Refractive Index: 1.591
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• CAS DataBase Reference: 3-BROMO-5-METHYLBENZONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BROMO-5-METHYLBENZONITRILE(124289-21-0)
• EPA Substance Registry System: 3-BROMO-5-METHYLBENZONITRILE(124289-21-0)

Safety Data

• Hazardous Substances Data: 124289-21-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-Bromo-5-methylbenzonitrile is used as a synthetic intermediate for the development of various pharmaceutical compounds. Its unique structure allows for the creation of new drug candidates with potential therapeutic applications.
Used in Chemical Research:
In the field of chemical research, 3-Bromo-5-methylbenzonitrile serves as a valuable compound for studying reaction mechanisms and exploring new synthetic pathways. Its reactivity and structural features make it an interesting subject for academic and industrial research.
Used in Material Science:
3-Bromo-5-methylbenzonitrile is utilized in the synthesis of arenes with high steric regiocontrol, which are essential in the development of advanced materials with specific properties. Its use in this context contributes to the advancement of material science and the creation of innovative products.
Used in Agrochemical Industry:
3-BROMO-5-METHYLBENZONITRILE also finds application in the agrochemical industry, where it is employed as a building block for the synthesis of various agrochemicals. Its role in this industry is crucial for the development of new pesticides and other agrochemical products that can improve crop yields and protect plants from pests.

InChI:InChI=1/C8H6BrN/c1-6-2-7(5-10)4-8(9)3-6/h2-4H,1H3

Upstream product

• 1611-92-3 3,5-dibromotoluene 
• 544-92-3 copper(I) cyanide 
• 1583285-83-9 C₂₀H₃₉BO₄Si₃ 
• 253342-48-2 4,4,5,5-tetramethyl-2-m-tolyl-1,3,2-dioxaborolane 
• 648439-19-4 (3-bromo-5-methylphenyl)methanol 
• 51719-69-8 1-bromo-3-(bromomethyl)-5-methylbenzene 
• 556-96-7 5-bromo-1,3-xylene 
• 591-17-3 meta-bromotoluene 
• 557-21-1 zinc(II) cyanide 
• 942069-53-6 2-(3-bromo-5-methylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 1205515-03-2 3-bromo-5-methylbenzaldehyde oxime 
• 1007578-82-6 3-bromo-5-methylbenzamide 
• 141-78-6 ethyl acetate 
• 13091-43-5 2-amino-3-bromo-5-methylbenzoic acid 

Downstream Products

• 1395093-32-9 3-bromo-N-(2,6-diisopropylphenyl)-5-methylbenziimidamide 
• 1177558-49-4 3-bromo-5-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]benzonitrile 
• 1177558-50-7 3-(aminomethyl)-5-bromobenzonitrile 
• 1177558-71-2 tert-butyl (3-bromo-5-cyanobenzyl)carbamate 
• 1177558-42-7 (3-bromo-5-methylphenyl)methanamine 
• 95658-81-4 3-hydroxy-5-methylbenzonitrile 

Relevant articles and documents

INTERMOLECULAR C-H SILYLATION OF UNACTIVATED ARENES

Reaction mixtures for silvlating arene substrates and methods of using such reaction mixtures to silyiate the arene substrates are provided. Exemplary reaction mixtures include the arene substrate, a liganded metal catalyst, a hydrogen acceptor and an organic solvent. The reaction conditions allow for diverse substituents on the arene substrate.

Rhodium-catalyzed intermolecular C-H silylation of arenes with high steric regiocontrol

Regioselective C-H functionalization of arenes has widespread applications in synthetic chemistry. The regioselectivity of these reactions is often controlled by directing groups or steric hindrance ortho to a potential reaction site. Here, we report a catalytic intermolecular C-H silylation of unactivated arenes that manifests very high regioselectivity through steric effects of substituents meta to a potential site of reactivity. The silyl moiety can be further functionalized under mild conditions but is also inert toward many common organic transformations, rendering the silylarene products useful building blocks. The remote steric effect that we observe results from the steric properties of both the rhodium catalyst and the silane.

Palladium(II)-catalyzed direct conversion of methyl arenes into aromatic nitriles

From methyl to nitrile: A mild ammoxidation method, which directly converts methyl arenes into aromatic nitriles, has been developed by using Pd(OAc) 2 and N-hydroxyphthalimide (NHPI) as the catalysts, and tert-butyl nitrite as the nitrogen source and oxidant. Copyright

NOVEL TETRADENTATE PLATINUM COMPLEXES

Novel phosphorescent tetradentate platinum (II) compounds comprising a twisted aryl group are provided. Also provided are novel phosphorescent tetradentate platinum (II) compounds comprising an imidazo[1,2-f]phenanthridine moiety. The compounds may be used in organic light emitting devices to provide improved device efficiency, line shape and lifetime.

Compounds and their use as BACE Inhibitors

The present invention relates to compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of Aβ-related pathologies such as Down's syndrome, β-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

PYRIDONE DERIVATIVES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS

The present invention relates to 2-pyridone derivatives of Formula (I) or (IV) as herein described, compositions containing such compounds, synthetic processes for making such compounds, and therapeutic methods that include the administration of such comp

DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS

The present invention is directed to novel compounds of Formula's (I) - (VI), and pharmaceutically acceptable salts thereof, pharmaceutical compositions and their use in therapy, for example as inhibitors of phosphodiesterase type IV (PDE4) and as antagonists of muscarinic acetylcholine receptors (mAChRs), in the treatment of and/or prophylaxis of respiratory diseases, including inflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.

Dual Pharmacophores - PDE4-Muscarinic Antagonistics

The present invention is directed to novel compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions and their use as dual chromaphores having inhibitory activity against PDE4 and muscarinic acetylcholine receptors (mAChRs), and thus being useful for treating respiratory diseases.

Dual Pharmacophores - PDE4-Muscarinic Antagonistics

The present invention relates to novel compounds of Formula (I) and their use in the treatment of respiratory diseases, including anti-inflammatory and allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.

Dual Pharmacophores - PDE4-Muscarinic Antagonistics

The present invention is directed to novel compounds of Formula (I), pharmaceutical compositions and their use in therapy, for example as inhibitors of phosphodiesterase type IV (PDE4) and as antagonists of muscarinic acetylcholine receptors (mAChRs), in the treatment of/and or prophylaxis of respiratory diseases, including antiinflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.